Join us for the official launch of DiMe’s Integrated Evidence Plans (IEP) resources, designed to help you overcome key challenges in evidence generation and commercial adoption of digital health technologies (DHTs)!
Join us for our launch, “Unlocking impact through investment: Building the business case for digital endpoints,” on Mar. 26 at 11 a.m. ET. Learn how new resources support you in measuring ROI and building your business case for digital endpoints.
Quantifying the Benefits of Digital Biomarkers and Technology-Based Study Endpoints in Clinical Trials: Project Moneyball
Date/Time
August 03, 2022
Discussion Topic
Have you ever been asked what tangible benefits digital biomarkers bring to clinical studies? Inspired by the book and film Moneyball, the authors developed a novel method to quantify the values of patient selection and endpoint technologies using Monte Carlo simulation. Their work illustrates the model and potential application using Parkinson’s Disease example. This presentation will discuss:
1. The project rationale and Moneyball metaphor
2. SV95C and its clinical study impact
3. Monte Carlo approach and the model
4. The results and the way forward
